Quetiapine in the Treatment of Anxiety in Patients With Bipolar I or II Depression: A Secondary Analysis From a Randomized, Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Quetiapine monotherapy shows efficacy in bipolar depression. The analyses in this multicenter, double-blind, randomized, fixed-dose, placebo-controlled study evaluated effects of quetiapine monotherapy on anxiety symptoms in bipolar depression. METHOD: Of 542 outpatients randomly assigned to treatment, 539 with bipolar I (N = 358) or bipolar II (N = 181) disorder experiencing a major depressive episode (DSM-IV) received 8 weeks of quetiapine monotherapy (600 or 300 mg/day) or placebo between September 2002 and October 2003. Anxiety assessments included the Hamilton Rating Scale for Anxiety (HAM-A) and relevant items from the Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Rating Scale for Depression (HAM-D). Analyses evaluated the pooled dose groups versus placebo. RESULTS: At week 8, quetiapine 600 and 300 mg/day each demonstrated significant improvements in HAM-A total score versus placebo (-10.8 and -9.9 vs. -6.7, p < .001). Quetiapine (pooled doses) significantly improved HAM-A total score from week 1. In bipolar I depression, quetiapine showed significant improvement in HAM-A total score versus placebo (-10.4 vs. -5.1, p < .001). In bipolar I depression, quetiapine also showed significant improvements versus placebo on the HAM-A anxious mood and tension items, HAM-A psychic and somatic subscales, MADRS inner tension item, and HAM-D psychic anxiety item (all p < .001), but not the HAM-D somatic anxiety item. In bipolar II depression, quetiapine reduced the HAM-A total score more than placebo, but the difference was not statistically significant (-9.8 vs. -9.0, p = .473). In bipolar II depression, quetiapine showed significant improvement versus placebo on the HAM-A anxious mood, MADRS inner tension, and HAM-D psychic anxiety items (all p < .01). CONCLUSION: Quetiapine monotherapy shows efficacy in treating anxiety symptoms in bipolar I depression; however, the anxiolytic effects in bipolar II disorder require further investigation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, secondary analyses from several RCTs indicate that quetiapine monotherapy significantly reduces symptoms of GAD and panic disorder in patients with bipolar depression.290, 313, 725”
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Self-citationAntidepressants and the Risk of Suicidal Behaviors
Jick, H. (2004) · JAMA · doi:10.1001/jama.292.3.338 · Cited by 578
Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia
Pini, S., Cassano, G. B., Simonini, E., Savino, M., Russo, A., & Montgomery, S. A. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)01405-x · Cited by 226
Impact of Comorbid Anxiety Disorders on Outcome in a Cohort of Patients With Bipolar Disorder
Boylan, K. R., Bieling, P. J., Marriott, M., Begin, H., Young, L. T., & MacQueen, G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0813 · Cited by 215
Subsyndromal Depression Is Associated With Functional Impairment in Patients With Bipolar Disorder
Altshuler, L. L., Gitlin, M. J., Mintz, J., Leight, K. L., & Frye, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0910 · Cited by 174
Atmaca, M., Kuloglu, M., Tezcan, E., & Gecici, O. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200205000-00004 · Cited by 149
Hamner, M. B., Deitsch, S. E., Brodrick, P. S., Ulmer, H. G., & Lorberbaum, J. P. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00003 · Cited by 147
Treating Impulsivity and Anxiety in the Suicidal Patient
Fawcett, J. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05800.x · Cited by 107
Pharmacotherapy for Bipolar Disorder and Comorbid Conditions: Baseline Data From STEP-BD
Simon, N. M., Otto, M. W., Weiss, R. D., Bauer, M. S., Miyahara, S., Wisniewski, S. R., Thase, M. E., Kogan, J., Frank, E., Nierenberg, A. A., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000138772.40515.70 · Cited by 106
CRF/NPY interactions: A potential role in sleep dysregulation in depression and anxiety
Ehlers, C. L., Somes, C., Seifritz, E., & Rivier, J. E. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)6:1<40::aid-da6>3.0.co;2-9 · Cited by 91
The Use of Placebo in Clinical Trials on Bipolar Disorder: A New Approach for an Old Debate
Vieta, E., & Carné, X. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082021 · Cited by 70
Placebo effect in randomized, controlled studies of acute bipolar mania and depression
Keck, P. E., Welge, J. A., McElroy, S. L., Arnold, L. M., & Strakowski, S. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00311-x · Cited by 64
Adson, D. E., Kushner, M. G., Eiben, K. M., & Schulz, S. C. (2004) · Depression and Anxiety · doi:10.1002/da.10137 · Cited by 59
The role of atypical antipsychotics in bipolar depression and anxiety disorders
McIntyre, R., & Katzman, M. (2003) · Bipolar Disorders · doi:10.1111/j.1399-2406.2003.00061.x · Cited by 54
Reevaluating therapies for bipolar depression.
Grunze, H. (2005) · PubMed · Cited by 53
Anxiety disorders comorbidity in mood disorder subgroups: data from a mood disorders clinic
Yerevanian, B. I., Koek, R. J., & Ramdev, S. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00448-7 · Cited by 38
Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania
Bowden, C. L., Davis, J., Morris, D., Swann, A., Calabrese, J., Lambert, M., & Goodnick, P. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)6:1<26::aid-da4>3.0.co;2-3 · Cited by 31
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“orders (see specific disorder sections for evidence), and data show that these agents can significantly reduce anxiety symptoms in patients with bipolar disorder [1409-1413].”
BackgroundYatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
“Two subanalyses of the BOLDER I data showed that among patients with BD II depression, quetiapine was effective in patients with rapid cycling (196), but anxiety scores (HAM-A) were not significantly improved (197).”
MethodMaher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Metadata
- Authors
- Hirschfeld, R. M. A., Weisler, R. H., Raines, S. R., Macfadden, W., & BOLDER Study Group
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- University of North Carolina at Chapel Hill (US)
- AstraZeneca (United Kingdom) (GB)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-03-15
- Volume
- 67
- Issue
- 03
- Pages
- 355-362
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2093305066
- Cited by
- 116
- References
- 23
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 5 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 2 · 2016: 2 · 2015: 13 · 2014: 7 · 2013: 3 · 2012: 9
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- quetiapine, bipolar depression, bipolar I disorder, bipolar II disorder, anxiety symptoms, anxiolytic effects, major depressive episode, Hamilton Anxiety Rating Scale, inner tension
- MeSH terms
- Quetiapine Fumarate, Adult, Ambulatory Care, Anxiety Disorders, Bipolar Disorder, Major Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Administration Schedule, Female, Humans, Longitudinal Studies, Male, Placebos, Psychiatric Status Rating Scales, Antipsychotic Agents, Comorbidity, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.